Pharma BD Deal Intelligence
Roche acquired Ignyta for ~$1.7B for cancer targeted therapies.
Roche snaps up Ignyta and entrectinib for $1.7 billion at $27 per share a 74 percent premium.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche acquired Ignyta for ~$1.7B for cancer targeted therapies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Ignyta Inc. (this deal) | 2017 | $1.7B | 73 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2017 deals · Roche Holding AG deals · Oncology deals